The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial
Abstract
Purpose: In a series of trials, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV) have been identified as effective treatments for Hodgkin’s disease. We compared these regimens as initial chemotherapy for Hodgkin’s disease. Patients and Methods: Adult patients (N = 856) with advanced Hodgkin’s disease were randomly assigned to treatment with ABVD or MOPP/ABV. The major end points were failure-free and overall survival, life-threatening acute toxicities, and serious long-term toxicities, including cardiomyopathy, pulmonary toxicity, myelodysplastic syndromes (MDS), and secondary malignancies. Results: The rates of complete remission (76% v 80%, P = .16), failure-free survival at 5 years (63% v 66%, P = .42), and overall survival at 5 years (82% v 81%, P = .82) were similar for ABVD and MOPP/ABV, respectively. Clinically significant acute pulmonary and hematologic toxicity were more common with MOPP/ABV (P = .060 and .001, respectively). There was no difference in cardiac toxicity. There were 24 deaths attributed to initial treatment: nine with ABVD and 15 with MOPP/ABV (P = .057). There have been 18 second malignancies associated with ABVD and 28 associated with MOPP/ABV (P = .13). Thirteen patients have developed MDS or acute leukemia: 11 were initially treated with MOPP/ABV, and two were initially treated with ABVD but subsequently received MOPP-containing regimens and radiotherapy before developing leukemia (P = .011). Conclusion: ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin’s disease. MOPP/ABV is associated with a greater incidence of acute toxicity, MDS, and leukemia. ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Self-citationChemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272102 · Cited by 1,148
Self-citationBreast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Analysing Survival Data From Clinical Trials and Observational Studies
(1996) · Technometrics · doi:10.1080/00401706.1996.10484530 · Cited by 663
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
DEVITA, V. T., SIMON, R. M., HUBBARD, S. M., YOUNG, R. C., BERARD, C. W., MOXLEY, J. H., FREI, E., CARBONE, P. P., & CANELLOS, G. P. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-5-587 · Cited by 468
Self-citationHorning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., & Rosenberg, S. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.630 · Cited by 324
Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
Valagussa, P., Santoro, A., Fossati-Bellani, F., Banfi, A., & Bonadonna, G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.830 · Cited by 303
Design and analysis of group sequential tests based on the type I error spending rate function
KIM, K., & DEMETS, D. L. (1987) · Biometrika · doi:10.1093/biomet/74.1.149 · Cited by 295
Pedersen-Bjergaard, J., & Larsen, S. O. (1982) · New England Journal of Medicine · doi:10.1056/nejm198210143071601 · Cited by 281
Glick, J. H., Young, M. L., Harrington, D. P., Schilsky, R. L., BECK, T. M., Neiman, R. S., Fisher, R. I., Peterson, B. A., & Oken, M. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.19 · Cited by 100
Self-citationExtending SAS® Survival Analysis Techniques for Medical Research
Cantor, A. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485216 · Cited by 75
Policies for interim analysis and interim reporting of results.
O'Fallon, J. R. (1985) · PubMed · Cited by 5
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Metadata
- Authors
- Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I., Connors, J. M., Canellos, G. P., & Peterson, B. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-02-15
- Volume
- 21
- Issue
- 4
- Pages
- 607-614
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2076334524
- Cited by
- 487
- References
- 16
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.